VF
KTTAW icon

Virtu Financial’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Virtu Financial’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-85,713
Closed -$1K – 1796
2023
Q3 		$1K Buy
+85,713
New +$1.77K ﹤0.01% 1190

Other funds holding KTTAW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial's KTTAW Position: Q4 2023 in Review

Virtu Financial sold out of Pasithea Therapeutics Warrants (KTTAW) in Q4 2023, closing a stake of 85,713 shares — an estimated $1K sold.

Virtu Financial first reported a position in KTTAW in Q3 2023 and held it in 1 quarter. The position peaked at $1K in Q3 2023. 5 funds tracked by Wall St. Rank hold KTTAW as of Q4 2023.

  • Virtu Financial reported no remaining Pasithea Therapeutics Warrants position as of Q4 2023 after selling out during the quarter.
  • Virtu Financial sold 85,713 Pasithea Therapeutics Warrants shares in Q4 2023, an estimated $1K.
  • Virtu Financial first reported a position in Pasithea Therapeutics Warrants in Q3 2023 and held it in 1 quarter.
  • Virtu Financial's Pasithea Therapeutics Warrants position peaked at $1K in Q3 2023.
  • 5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.